{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:17:23Z","timestamp":1791605843713,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Aegerion Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12020-018-1589-1","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T22:28:47Z","timestamp":1523485727000},"page":"479-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy"],"prefix":"10.1007","volume":"60","author":[{"given":"Rebecca J.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif A.","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Cochran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ara\u00fajo-Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Salinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Gorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"1589_CR1","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"R.J. Brown, D. Araujo-Vilar, P.T. Cheung, D. Dunger, A. Garg, M. Jack, L. Mungai, E.A. Oral, N. Patni, K.I. Rother, J. von Schnurbein, E. Sorkina, T. Stanley, C. Vigouroux, M. Wabitsch, R. Williams, T. Yorifuji, The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J. Clin. Endocrinol. Metab. 101, 4500\u20134511 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1589_CR2","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","volume":"87","author":"WA Haque","year":"2002","unstructured":"W.A. Haque, I. Shimomura, Y. Matsuzawa, A. Garg, Serum adiponectin and leptin levels in patients with lipodystrophies. J. Clin. Endocrinol. Metab. 87, 2395 (2002)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1589_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/372425a0","volume":"372","author":"Y Zhang","year":"1994","unstructured":"Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425\u2013432 (1994)","journal-title":"Nature"},{"key":"1589_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","volume":"19","author":"Y Handelsman","year":"2013","unstructured":"Y. Handelsman, E.A. Oral, Z.T. Bloomgarden, R.J. Brown, J.L. Chan, D. Einhorn, A.J. Garber, A. Garg, W.T. Garvey, G. Grunberger, R.R. Henry, N. Lavin, C.D. Tapiador, C. Weyer, The clinical approach to the detection of lipodystrophy\u2014an AACE consensus statement. Endocr. Pract. 19, 107\u2013116 (2013)","journal-title":"Endocr. Pract."},{"key":"1589_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","volume":"87","author":"A Bingham","year":"2008","unstructured":"A. Bingham, G. Mamyrova, K.I. Rother, E. Oral, E. Cochran, A. Premkumar, D. Kleiner, L. James-Newton, I.N. Targoff, J.P. Pandey, D.M. Carrick, N. Sebring, T.P. O\u2019Hanlon, M. Ruiz-Hidalgo, M. Turner, L.B. Gordon, J. Laborda, S.R. Bauer, P.J. Blackshear, L. Imundo, F.W. Miller, L.G. Rider, Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine 87, 70\u201386 (2008)","journal-title":"Medicine"},{"key":"1589_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1023\/A:1021827520301","volume":"4","author":"EA Oral","year":"2003","unstructured":"E.A. Oral, Lipoatrophic diabetes and other related syndromes. Rev. Endocr. Metab. Disord. 4, 61\u201377 (2003)","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"1589_CR7","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMra025261","volume":"350","author":"A Garg","year":"2004","unstructured":"A. Garg, Acquired and inherited lipodystrophies. N. Engl. J. Med. 350, 1220\u20131234 (2004)","journal-title":"N. Engl. J. Med."},{"key":"1589_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/17512433.2016.1096772","volume":"9","author":"CA Meehan","year":"2016","unstructured":"C.A. Meehan, E. Cochran, A. Kassai, R.J. Brown, P. Gorden, Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev. Clin. Pharmacol. 9, 59\u201368 (2016)","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"1589_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrendo.2015.123","volume":"11","author":"N Patni","year":"2015","unstructured":"N. Patni, A. Garg, Congenital generalized lipodystrophies\u2014new insights into metabolic dysfunction. Nat. Rev. Endocrinol. 11, 522\u2013534 (2015)","journal-title":"Nat. Rev. Endocrinol."},{"key":"1589_CR10","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"M. Miller, N.J. Stone, C. Ballantyne, V. Bittner, M.H. Criqui, H.N. Ginsberg, A.C. Goldberg, W.J. Howard, M.S. Jacobson, P.M. Kris-Etherton, T.A. Lennie, M. Levi, T. Mazzone, S. Pennathur, Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123, 2292\u20132333 (2011)","journal-title":"Circulation"},{"key":"1589_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40265-013-0074-7","volume":"73","author":"K Chou","year":"2013","unstructured":"K. Chou, C.M. Perry, Metreleptin: first global approval. Drugs 73, 989\u2013997 (2013)","journal-title":"Drugs"},{"key":"1589_CR12","unstructured":"Myalept [Package Insert] (Aegerion Pharmaceuticals, Inc., Cambridge, MA, 2015)"},{"key":"1589_CR13","doi-asserted-by":"publisher","first-page":"922","DOI":"10.4158\/EP11229.OR","volume":"17","author":"JL Chan","year":"2011","unstructured":"J.L. Chan, K. Lutz, E. Cochran, W. Huang, Y. Peters, C. Weyer, P. Gorden, Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr. Pract. 17, 922\u2013932 (2011)","journal-title":"Endocr. Pract."},{"key":"1589_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","volume":"53","author":"AY Chong","year":"2010","unstructured":"A.Y. Chong, B.C. Lupsa, E.K. Cochran, P. Gorden, Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53, 27\u201335 (2010)","journal-title":"Diabetologia"},{"key":"1589_CR15","doi-asserted-by":"publisher","first-page":"E1493","DOI":"10.1210\/jc.2014-1353","volume":"99","author":"JD Christensen","year":"2014","unstructured":"J.D. Christensen, A.O. Lungu, E. Cochran, M.T. Collins, R.I. Gafni, J.C. Reynolds, K.I. Rother, P. Gorden, R.J. Brown, Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J. Clin. Endocrinol. Metab. 99, E1493\u2013E1500 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1589_CR16","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2014-4491","volume":"100","author":"T Diker-Cohen","year":"2015","unstructured":"T. Diker-Cohen, E. Cochran, P. Gorden, R.J. Brown, Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J. Clin. Endocrinol. Metab. 100, 1802\u20131810 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1589_CR17","doi-asserted-by":"publisher","first-page":"E1676","DOI":"10.1210\/jc.2014-1878","volume":"99","author":"J Joseph","year":"2014","unstructured":"J. Joseph, R.D. Shamburek, E.K. Cochran, P. Gorden, R.J. Brown, Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides. J. Clin. Endocrinol. Metab. 99, E1676\u2013E1680 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1589_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000341398","volume":"78","author":"F Kamran","year":"2012","unstructured":"F. Kamran, K.I. Rother, E. Cochran, E. Safar Zadeh, P. Gorden, R.J. Brown, Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. Horm. Res. Paediatr. 78, 320\u2013325 (2012)","journal-title":"Horm. Res. Paediatr."},{"key":"1589_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jacl.2017.02.002","volume":"11","author":"R Muniyappa","year":"2017","unstructured":"R. Muniyappa, B.S. Abel, A. Asthana, M.F. Walter, E.K. Cochran, A.T. Remaley, M.C. Skarulis, P. Gorden, R.J. Brown, Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy. J. Clin. Lipidol. 11, 543\u2013550 (2017)","journal-title":"J. Clin. Lipidol."},{"key":"1589_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJMoa012437","volume":"346","author":"EA Oral","year":"2002","unstructured":"E.A. Oral, V. Simha, E. Ruiz, A. Andewelt, A. Premkumar, P. Snell, A.J. Wagner, A.M. DePaoli, M.L. Reitman, S.I. Taylor, P. Gorden, A. Garg, Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570\u2013578 (2002)","journal-title":"N. Engl. J. Med."},{"key":"1589_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1210\/jc.2006-1546","volume":"92","author":"K Ebihara","year":"2007","unstructured":"K. Ebihara, T. Kusakabe, M. Hirata, H. Masuzaki, F. Miyanaga, N. Kobayashi, T. Tanaka, H. Chusho, T. Miyazawa, T. Hayashi, K. Hosoda, Y. Ogawa, A.M. DePaoli, M. Fukushima, K. Nakao, Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J. Clin. Endocrinol. Metab. 92, 532\u2013541 (2007)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1589_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/dom.12606","volume":"18","author":"C Vatier","year":"2016","unstructured":"C. Vatier, S. Fetita, P. Boudou, C. Tchankou, L. Deville, J. Riveline, J. Young, L. Mathivon, F. Travert, D. Morin, J. Cahen, O. Lascols, F. Andreelli, Y. Reznik, E. Mongeois, I. Madelaine, M. Vantyghem, J. Gautier, C. Vigouroux, One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes Obes. Metab. 18, 693\u2013697 (2016)","journal-title":"Diabetes Obes. Metab."},{"key":"1589_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12020-014-0450-4","volume":"49","author":"D Araujo-Vilar","year":"2015","unstructured":"D. Araujo-Vilar, S. Sanchez-Iglesias, C. Guillin-Amarelle, A. Castro, M. Lage, M. Pazos, J.M. Rial, J. Blasco, E. Guillen-Navarro, R. Domingo-Jimenez, M.R. del Campo, B. Gonzalez-Mendez, F.F. Casanueva, Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience. Endocrine 49, 139\u2013147 (2015)","journal-title":"Endocrine"},{"key":"1589_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4137\/CCRep.S40196","volume":"9","author":"C Musso","year":"2016","unstructured":"C. Musso, M.L. Major, E. Andres, V. Simha, Metreleptin treatment in three patients with generalized lipodystrophy. Clin. Med. Insights Case Rep. 9, 123\u2013127 (2016)","journal-title":"Clin. Med. Insights Case Rep."},{"key":"1589_CR25","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1542\/peds.2006-3165","volume":"120","author":"J Beltrand","year":"2007","unstructured":"J. Beltrand, M. Beregszaszi, D. Chevenne, G. Sebag, M. De Kerdanet, F. Huet, M. Polak, N. Tubiana-Rufi, D. Lacombe, A.M. De Paoli, C. Levy-Marchal, Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics 120, e291\u2013e296 (2007)","journal-title":"Pediatrics"},{"key":"1589_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/10428194.2015.1040015","volume":"57","author":"RJ Brown","year":"2016","unstructured":"R.J. Brown, J.L. Chan, E.S. Jaffe, E. Cochran, A.M. DePaoli, J.F. Gautier, C. Goujard, C. Vigouroux, P. Gorden, Lymphoma in acquired generalized lipodystrophy. Leuk. Lymphoma 57, 45\u201350 (2016)","journal-title":"Leuk. Lymphoma"},{"key":"1589_CR27","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1016\/j.ejca.2015.08.031","volume":"51","author":"AV Hernandez","year":"2015","unstructured":"A.V. Hernandez, V. Pasupuleti, V.A. Benites-Zapata, P. Thota, A. Deshpande, F.R. Perez-Lopez, Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis. Eur. J. Cancer 51, 2747\u20132758 (2015)","journal-title":"Eur. J. Cancer"},{"key":"1589_CR28","doi-asserted-by":"publisher","first-page":"789174","DOI":"10.1155\/2012\/789174","volume":"2012","author":"B Arcidiacono","year":"2012","unstructured":"B. Arcidiacono, S. Iiritano, A. Nocera, K. Possidente, M.T. Nevolo, V. Ventura, D. Foti, E. Chiefari, A. Brunetti, Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp. Diabetes Res. 2012, 789174 (2012)","journal-title":"Exp. Diabetes Res."},{"key":"1589_CR29","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.1038\/onc.2017.107","volume":"36","author":"X Wang","year":"2017","unstructured":"X. Wang, M.F. Haring, T. Rathjen, S.M. Lockhart, D. Sorensen, S. Ussar, L.M. Rasmussen, M.M. Bertagnolli, C.R. Kahn, C. Rask-Madsen, Insulin resistance in vascular endothelial cells promotes intestinal tumour formation. Oncogene 36, 4987\u20134996 (2017)","journal-title":"Oncogene"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-1589-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T20:31:10Z","timestamp":1555014670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-018-1589-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1589"],"URL":"https:\/\/doi.org\/10.1007\/s12020-018-1589-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733036725.793565864","asserted-by":"object"}]},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]},"assertion":[{"value":"9 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"E.A.O. has served as a consultant to Aegerion, Akcea, AstraZeneca, and Regeneron, received grants from Aegerion, Akcea, AstraZeneca, Gemphire, GIDynamics, and received non-material support from Aegerion and Boehringer Ingelheim. D.A.V. and D.B.S. have served as consultants to Aegerion Pharmaceuticals. A.L. and G.F. are employees of Aegerion Pharmaceuticals. T.S. is a former employee of Aegerion Pharmaceuticals. R.J.B., E.C., and P.G. declares that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}